Specify a stock or a cryptocurrency in the search bar to get a summary
PolyPid
PYPDPolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376
Analytics
WallStreet Target Price
14 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PYPD
Dividend Analytics PYPD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PYPD
Stock Valuation PYPD
Financials PYPD
Results | 2019 | Dynamics |